MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.27B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 4.08M
Average 5.73M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +79.2% (5yr)5 analysts |
| Revenue | N/A | N/A | +51.8% | +13.8% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | +81.7% (5yr)6 analysts |
| EBIT | N/A | N/A | N/A | +34.8% (5yr)6 analysts |
Analysis
Recent growth has been strongest in Revenue at +51.8% over three years. Forward estimates point to Net Income at +81.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Xeris Biopharma Holdings, Inc. NASDAQ:XERS | $3.04B | $16.66 | Undervalued | 98.7 | +142.98% |
Avalyn Pharma Inc. Common Stock NASDAQ:AVLN | $1.34B | $30.28 | Not rated | — | — |
Theravance Biopharma, Inc. NASDAQ:TBPH | $884.18M | $17.03 | Undervalued | 7.4 | -4.86% |
ARS Pharmaceuticals, Inc. NASDAQ:SPRY | $391.05M | $3.89 | Not rated | -4.8 | -50.07% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | $3.71 | Not rated | 1.4 | +63.27% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $94.82M | $2.19 | Not rated | -5.3 | +25.62% |
Continue the stock analysis
Jump to another research area for this company.